Roberto Arrojo
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 3
- PARP inhibition in cancer therapy 3
-
- Cancer therapeutics and mechanisms 2
- DNA Repair Mechanisms 2
- Co-authors
- Thomas M. Cardillo (10 shared papers)David M. Goldenberg (10 shared papers)Robert M. Sharkey (7 shared papers)Chien‐Hsing Chang (5 shared papers)Preeti Trisal (2 shared papers)Donglin Liu (2 shared papers)Serengulam V. Govindan (6 shared papers)Edmund A. Rossi (2 shared papers)
- Journals
- Cancer Research (5 papers)Oncotarget (2 papers)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)Bioconjugate Chemistry (1 paper)
- Partner nations
- United States
In The Last Decade
Roberto Arrojo
11 papers receiving 376 citations
Peers
Comparison fields: 5 of 39
- Oncology 308
- Radiology, Nuclear Medicine and Imaging 148
- Pulmonary and Respiratory Medicine 95
- Cancer Research 36
- Molecular Biology 133
Countries citing papers authored by Roberto Arrojo
This map shows the geographic impact of Roberto Arrojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Arrojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Arrojo more than expected).
Fields of papers citing papers by Roberto Arrojo
This network shows the impact of papers produced by Roberto Arrojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Arrojo. The network helps show where Roberto Arrojo may publish in the future.
Co-authors
The 13 scholars most cited alongside Roberto Arrojo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 209 | |
| 2 | 2017 | 98 | |
| 3 | 2020 | 32 | |
| 4 | 2013 | 28 | |
| 5 | 2024 | 9 | |
| 6 | 2010 | 4 | |
| 7 | 2010 | 4 | |
| 8 | 2012 | 4 | |
| 9 | 2016 | 2 | |
| 10 | 2016 | 1 | |
| 11 | 2015 | 1 |
About Roberto Arrojo
Roberto Arrojo is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Surgery, having authored 11 papers that have together received 392 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (4 papers), Cancer Treatment and Pharmacology (3 papers), HER2/EGFR in Cancer Research (3 papers), PARP inhibition in cancer therapy (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Cancer therapeutics and mechanisms (2 papers), DNA Repair Mechanisms (2 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Oncology (308 citations), Radiology, Nuclear Medicine and Imaging (148 citations), Pulmonary and Respiratory Medicine (95 citations), Cancer Research (36 citations) and Molecular Biology (133 citations). Roberto Arrojo has collaborated with scholars based in United States. Frequent co-authors include Thomas M. Cardillo, David M. Goldenberg, Robert M. Sharkey, Chien‐Hsing Chang, Preeti Trisal, Donglin Liu, Serengulam V. Govindan, Edmund A. Rossi, Diane L. Rossi and Sung-Ju Moon. Their work appears in journals such as Cancer Research, Oncotarget, Molecular Cancer Therapeutics, Clinical Cancer Research and Bioconjugate Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.